Every year, around 300,000 children are born worldwide with β-thalassaemia, a type of hereditary anaemia that, that it presents asymptomatically in most cases, can become fatal. With around 250 million people affected, β-thalassaemia is estimated to be the most common hereditary disease at global level. This β-thalassaemia, moreover, is also known as “Mediterranean anaemia”, since it is most common in the Mediterranean basin.
β-Thalassaemia treatment. Now, researchers from Yale University in New Haven (United States) have discovered a new β-thalassaemia treatment using genetic engineering technique to cure it; the method uses “pieces” of synthetic DNA that are then administered intravenously, and can correct the mutations that cause beta β-thalassaemia.(See HERE).
La entrada Mediterranean anaemia can be treated using gene therapy aparece primero en Observatorio de Bioética, UCV.
Source: Bioethics Observatory.
This article was originally published by the Bioethics Observatory of the Catholic University of Valencia. Up-to-date news and reports from the Bioethics Observatory at the Catholic University of Valencia (Spain), covering a wide range of bioethical issues including stem cell research, abortion, assisted suicide and much more. General interest and specialised topical articles with ethical implications, based on the latest research findings from some of the world's top medical and scientific journals.
The views, opinions and positions expressed by these authors and blogs are theirs and do not necessarily represent that of the Bioethics Research Library and Kennedy Institute of Ethics or Georgetown University.